Want to see IN:THYROCARE full AI Analyst Report?
THYROCARE Stock Chart & Stats
₹459.10
-₹16.20(-1.70%)
At close: 4:00 PM EST
₹459.10
-₹16.20(-1.70%)
Day’s Range― - ―
52-Week Range₹342.55 - ₹578.05
Previous CloseN/A
Volume114.81K
Average Volume (3M)56.30K
Market Cap
₹85.07B
Enterprise Value₹28.13B
Total Cash (Recent Filing)₹2.20B
Total Debt (Recent Filing)₹506.90M
Price to Earnings (P/E)24.3
Beta0.66
Next Earnings
Aug 04, 2026EPS Estimate
6.63Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)21.22
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)9.48
Price to Sales (P/S)6.69
P/FCF Ratio28.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.9
Revenue Forecast (FY)₹9.68B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA conservatively leveraged balance sheet (debt-to-equity ~0.09) gives Thyrocare durable financial flexibility. Low leverage supports ongoing investment in lab automation and network expansion, helps absorb demand shocks, and preserves capacity for opportunistic M&A or capital allocation.
Strong Cash GenerationRobust cash conversion—operating cash exceeding net income and FCF close to reported earnings—provides lasting funding for maintenance and growth capex, franchise/channel support and shareholder returns. Strong cash flow reduces reliance on external financing for strategic initiatives.
Scalable Lab & Collection ModelA centralized automated-lab model with an extensive collection network creates scalable, lower per-test costs and high throughput. This structural setup supports volume-driven margins, repeatable unit economics and higher barriers to entry for smaller regional competitors over the medium term.
Bears Say
Margin VolatilityNotable margin volatility, particularly in gross margin, undermines the predictability of future earnings. Variable margins driven by test mix, pricing and utilization can complicate long-term planning, capital allocation and the sustainability of current profit levels.
Uneven Free Cash Flow GrowthWhile FCF surged in FY2026, historical unevenness in free cash flow growth signals sensitivity to operational cycles or timing of working capital. Irregular FCF can limit the company's ability to commit to steady capex, dividends, or buybacks through downturns without drawing on reserves.
Rising Debt TrendAlthough leverage remains low, the uptick in debt in FY2026 indicates growing balance-sheet usage. If the trend continues, it could gradually erode financial flexibility and increase fixed obligations, constraining investment and shareholder return optionality in adverse scenarios.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹342.55 and its highest was ₹578.05 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹85.07B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is Aug 04, 2026 which is in 23 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on May 07, 2026. The company reported ₹3.18 earnings per share for the quarter, missing the consensus estimate of ₹5.4 by -₹2.22.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate is 6.63.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹3.18 in its last earnings report, missing expectations of ₹5.4. Following the earnings report the stock price went up 1.737%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―